Jupiter Neurosciences has launched a new line of consumer supplements named Nugevia, focusing on health and performance in the longevity market.

The initial product offerings will include three formulations aimed at enhancing mitochondrial function, cognitive performance, and overall internal wellness, with plans to launch in the third quarter of 2025.

These supplements utilize an 'intelligent stacking' strategy, combining resveratrol with other synergistic compounds to optimize cellular health and improve delivery across the blood-brain barrier.

Resveratrol, known for its anti-aging and anti-inflammatory properties, has faced limitations in clinical use due to poor absorption, but Jupiter claims its proprietary technology significantly enhances this.

The supplements leverage Jupiter's proprietary micellar resveratrol delivery technology, JOTROL, which reportedly improves resveratrol absorption by ninefold and minimizes gastrointestinal side effects.

This launch follows Jupiter's successful IPO in December 2024, where the company raised $11 million to bolster both its commercial and clinical initiatives.

Revenue generated from Nugevia is earmarked to support ongoing clinical trials, including a Phase 2a trial for Parkinson's disease, following promising results from Phase 1.

CEO Christer Rosén highlighted that Nugevia serves as a strategic growth engine, reinforcing the company's therapeutic pipeline and enhancing shareholder value.

Despite resveratrol's recognized benefits, its clinical application has been limited, making Jupiter's advancements particularly noteworthy in the health supplement industry.